Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brianna M Lax

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 17, 2022
Correction to: Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity MaturationByong H Kang, Brianna M Lax, K Dane Wittrup
Methods in Molecular Biology (Clifton, N.J.)|April 28, 2022
Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity MaturationByong H Kang, Brianna M Lax, K Dane Wittrup
ACS Omega|February 16, 2026
Enzymatic Glucosylation Enhances the Solubility of Niclosamide but Abrogates Its Therapeutic EfficacyBrianna M Lax, Martina Escorial García, Carlota Fernandez-Antunez, et al.
Mabs|August 4, 2022
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapySarah C Cowles, Allison Sheen, Luciano Santollani, et al.
Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.
Nature Communications|March 1, 2024
CD8<sup>+</sup> T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8<sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|June 17, 2022
Correction to: Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity MaturationByong H Kang, Brianna M Lax, K Dane Wittrup
Methods in Molecular Biology (Clifton, N.J.)|April 28, 2022
Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity MaturationByong H Kang, Brianna M Lax, K Dane Wittrup
ACS Omega|February 16, 2026
Enzymatic Glucosylation Enhances the Solubility of Niclosamide but Abrogates Its Therapeutic EfficacyBrianna M Lax, Martina Escorial García, Carlota Fernandez-Antunez, et al.
Mabs|August 4, 2022
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapySarah C Cowles, Allison Sheen, Luciano Santollani, et al.
Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.
Nature Communications|March 1, 2024
CD8<sup>+</sup> T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8<sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.
Pageof 1